NovaGo Therapeutics Secures $30 Million Funding for Spinal Cord Injury Study

NovaGo Therapeutics Secures Funding for Groundbreaking Research

NovaGo Therapeutics AG, a Swiss biotechnology firm dedicated to developing biological drugs targeting Nogo-A, has made significant strides in its efforts to advance treatments for spinal cord injuries. Recently, the company successfully closed a Series B financing round, raising an impressive $30 million. This funding is essential for their upcoming proof-of-concept (PoC) study aimed at addressing acute spinal cord injuries, an area of critical unmet medical need.

The financing round was led by Neurimmune and Pureos, with contributions from both existing and new investors. In addition, funding from the Swiss Foundation for Paraplegics and Wings for Life provided crucial non-dilutive capital. With this financial backing, NovaGo is poised to push forward its primary program into a randomized, double-blind study involving 120 patients across clinical centers in Germany, Spain, and Switzerland.

Spinal cord injuries remain an area lacking effective regenerative treatment options that can restore lost neurological function. The primary focus of NovaGo is the inhibitory protein Nogo-A, which plays a significant role in preventing nerve fiber regeneration and neuroplasticity within the central nervous system. By targeting this protein, NovaGo aims to enhance functional recovery for those impacted by such injuries.

Professor Martin Schwab, Chief Scientific Officer of NovaGo, expressed excitement regarding the progress towards this crucial stage of clinical trials, emphasizing the importance of developing effective treatments for those living with the consequences of spinal cord injuries.

Furthermore, Professor Roger M. Nitsch, CEO of Neurimmune, highlighted the innovative approach being taken in collaboration with NovaGo. This novel therapeutic strategy employs a fully human antibody designed to promote nerve regeneration post-injury. Encouraging results from Phase 1 trials with their candidate NG004 have set a positive tone for the future of this program, as both partners work together to advance development efforts.

Dominik Escher, Managing Partner of Pureos Bioventures, also expressed satisfaction in co-leading the funding initiative, recognizing the promising results from NovaGo’s Phase 1 study as a sign of the potential for a breakthrough treatment option in spinal cord regeneration.

As the CEO of NovaGo Therapeutics, Stefan Moese, noted, the support received from investors and foundations alike has been instrumental in reaching this pivotal phase of development. With funding now secured, NovaGo is ready to move forward diligently in the pursuit of delivering a much-needed treatment solution for patients grappling with the severe impacts of spinal cord injuries.

In conclusion, the recent financing secured by NovaGo Therapeutics marks a significant step towards offering innovative solutions for those affected by spinal cord injuries. The firm’s ongoing research into anti-Nogo-A therapies has the potential to change lives, and the collaborative efforts with key partners demonstrate a strong commitment to advancing healthcare in this vital area. As the study progresses, the hope is that it will pave the way for the first effective regenerative treatments tailored to restore neurological function following spinal injury.